David Thompson

Corporate Officer/Principal at INOZYME PHARMA, INC.

Consumer Services

Health Technology

Profile

David Thompson is the founder of Azure Biotech, Inc. He is currently a Member-Scientific Advisory Board & Senior Advisor at Inozyme Pharma, Inc. His former position at Inozyme Pharma, Inc. was Chief Scientific Officer & Senior Vice President from 2018 to 2020.
Dr. Thompson has a graduate and doctorate degree from the University of Connecticut and a graduate degree from The University of Montana.

David Thompson active positions

Companies	Position	Start
INOZYME PHARMA, INC.	Corporate Officer/Principal	30/06/2021

All active positions of David Thompson

Former positions of David Thompson

Companies	Position	End
INOZYME PHARMA, INC.	Chief Tech/Sci/R&D Officer	12/10/2020
Azure Biotech, Inc. Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson.	Founder	-

See the detail of David Thompson's experience

Training of David Thompson

University of Connecticut	Doctorate Degree
The University of Montana	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David Thompson's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
INOZYME PHARMA, INC.	Health Technology

Private companies	1
Azure Biotech, Inc. Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson.	Health Technology